尼日利亚开始使用长效艾滋病毒预防注射Lenacapavir来抗击艾滋病毒流行病。 Nigeria begins using long-acting HIV prevention injection, Lenacapavir, to combat HIV epidemic.

尼日利亚每年两次接受长效艾滋病毒预防注射Lenacapavir,这是尼日利亚在防治艾滋病毒流行病方面迈出的重大一步。 Nigeria has received Lenacapavir, a long-acting HIV prevention injection given twice yearly, marking a major step in its fight against the HIV epidemic. 尼日利亚和其他119个低收入和中等收入国家通过自愿发放许可证,每年以40美元提供这种药物,这为每日口服PREP提供了更方便的替代药物,改善了对高风险人口的遵守情况。 The drug, available at $40 annually in Nigeria and 119 other low- and middle-income countries through voluntary licensing, offers a more convenient alternative to daily oral PrEP, improving adherence for high-risk populations. Lenacapavir得到联邦政府批准,并获得全球基金的支持,是尼日利亚减少新感染和结束艾滋病毒这一公共卫生威胁战略的一部分。 Approved by the federal government and supported by the Global Fund, Lenacapavir is part of Nigeria’s strategy to reduce new infections and end HIV as a public health threat. 由全国艾滋病毒、病毒性肝炎和性病控制方案牵头的推广工作旨在扩大获得服务的机会,加强预防服务,并解决母婴传播等差距。 The rollout, led by the National HIV, Viral Hepatitis and STDs Control Programme, aims to expand access, strengthen prevention services, and address gaps like mother-to-child transmission.